0000899243-17-012357.txt : 20170508 0000899243-17-012357.hdr.sgml : 20170508 20170508203257 ACCESSION NUMBER: 0000899243-17-012357 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170504 FILED AS OF DATE: 20170508 DATE AS OF CHANGE: 20170508 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Enright William CENTRAL INDEX KEY: 0001705564 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 17824132 MAIL ADDRESS: STREET 1: 19 FIRSTFIELD RD., SUITE 200 CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-05-04 0 0001326190 Altimmune, Inc. NASDAQ:ALT 0001705564 Enright William 19 FIRSTFIELD ROAD, SUITE 200 GAITHERSBURG MD 20878 1 1 0 0 See Remarks Common Stock, par value $0.0001 2017-05-04 4 A 0 17787 A 17787 D Stock Options (option to buy) 2.59 2017-05-04 4 A 0 125887 A 2017-05-04 2018-05-31 Common Stock, par value $0.0001 125887 125887 D Stock Options (option to buy) 0.08 2017-05-04 4 A 0 71644 A 2017-05-04 2019-12-31 Common Stock, par value $0.0001 71644 71644 D Stock Options (option to buy) 0.08 2017-05-04 4 A 0 91733 A 2017-05-04 2021-12-03 Common Stock, par value $0.0001 91733 91733 D Stock Options (option to buy) 0.08 2017-05-04 4 A 0 183347 A 2017-05-04 2021-12-03 Common Stock, par value $0.0001 183347 183347 D Stock Options (option to buy) 6.50 2017-05-04 4 A 0 99927 A 2027-05-04 Common Stock, par value $0.0001 99927 99927 D Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. On the first anniversary of the date of grant, 25% of the unvested portion of the option will become vested and exercisable, and the aggregate remaining unvested portion will vest and become exercisable in equal monthly installments over the 36-month period following such anniversary date. However, the agreement also provides that, if the compensation committee of the Issuer's board of directors, in its sole discretion, determines that the consummation of the mergers was successful, then 50% of the unvested portion of the option shall become immediately vested and exercisable. Granted under the terms of the Altimmune 2017 Omnibus Incentive Plan. President and Chief Executive Officer /s/ Ori Solomon, Attorney in fact for William Enright 2017-05-08